Long‐term outcome of quetiapine use for psychosis among parkinsonian patients
Identifieur interne : 002978 ( Istex/Checkpoint ); précédent : 002977; suivant : 002979Long‐term outcome of quetiapine use for psychosis among parkinsonian patients
Auteurs : Hubert H. Fernandez [États-Unis] ; Martha E. Trieschmann [États-Unis] ; Monica A. Burke [États-Unis] ; Carol Jacques [États-Unis] ; Joseph H. Friedman [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2003-05.
English descriptors
Abstract
To evaluate the long‐term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)‐motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L‐dopa) dose of 415 mg/d. Seventy‐eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty‐seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non‐responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95% CI = 1.4–92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07). © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10374
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:6159FF1947C0AC2C81DB7C5DD6A0CC90714C4972Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term outcome of quetiapine use for psychosis among parkinsonian patients</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name></author><author><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E." last="Trieschmann">Martha E. Trieschmann</name></author><author><name sortKey="Burke, Monica A" sort="Burke, Monica A" uniqKey="Burke M" first="Monica A." last="Burke">Monica A. Burke</name></author><author><name sortKey="Jacques, Carol" sort="Jacques, Carol" uniqKey="Jacques C" first="Carol" last="Jacques">Carol Jacques</name></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6159FF1947C0AC2C81DB7C5DD6A0CC90714C4972</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/mds.10374</idno><idno type="url">https://api.istex.fr/document/6159FF1947C0AC2C81DB7C5DD6A0CC90714C4972/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002861</idno><idno type="wicri:Area/Istex/Curation">002861</idno><idno type="wicri:Area/Istex/Checkpoint">002978</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term outcome of quetiapine use for psychosis among parkinsonian patients</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E." last="Trieschmann">Martha E. Trieschmann</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Burke, Monica A" sort="Burke, Monica A" uniqKey="Burke M" first="Monica A." last="Burke">Monica A. Burke</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Jacques, Carol" sort="Jacques, Carol" uniqKey="Jacques C" first="Carol" last="Jacques">Carol Jacques</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2003-05">2003-05</date><biblScope unit="vol">18</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="510">510</biblScope><biblScope unit="page" to="514">514</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">6159FF1947C0AC2C81DB7C5DD6A0CC90714C4972</idno><idno type="DOI">10.1002/mds.10374</idno><idno type="ArticleID">MDS10374</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Drug‐induced psychosis</term><term>Parkinson's disease</term><term>dementia</term><term>long‐term</term><term>quetiapine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate the long‐term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)‐motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L‐dopa) dose of 415 mg/d. Seventy‐eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty‐seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non‐responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95% CI = 1.4–92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07). © 2003 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Rhode Island</li></region></list><tree><country name="États-Unis"><region name="Rhode Island"><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name></region><name sortKey="Burke, Monica A" sort="Burke, Monica A" uniqKey="Burke M" first="Monica A." last="Burke">Monica A. Burke</name><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><name sortKey="Jacques, Carol" sort="Jacques, Carol" uniqKey="Jacques C" first="Carol" last="Jacques">Carol Jacques</name><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E." last="Trieschmann">Martha E. Trieschmann</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002978 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 002978 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Checkpoint
|type= RBID
|clé= ISTEX:6159FF1947C0AC2C81DB7C5DD6A0CC90714C4972
|texte= Long‐term outcome of quetiapine use for psychosis among parkinsonian patients
}}
| This area was generated with Dilib version V0.6.23. |  |